Empagliflozin and metformin and Orilissa
Determining the interaction of Empagliflozin and metformin and Orilissa and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Elagolix may increase the blood levels and effects of empagliflozin. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with elagolix may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, kidney, and/or liver due to inhibition of P-gp-mediated efflux by elagolix. When a single 0.5 mg dose of the probe P-gp substrate digoxin was coadministered with elagolix (200 mg twice daily for 10 days) in 11 study subjects, digoxin peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 71% and 26%, respectively, compared digoxin administered alone.
MANAGEMENT: Caution is advised when elagolix is used concurrently with drugs that are P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elagolix is added to or withdrawn from therapy.
- "Product Information. Orilissa (elagolix)." AbbVie US LLC, North Chicago, IL.
Generic Name: empagliflozin / metformin
Brand name: Synjardy, Synjardy XR
Synonyms: Empagliflozin and Metformin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Empagliflozin and metformin-Oritavancin
- Empagliflozin and metformin-Oritavancin Diphosphate
- Empagliflozin and metformin-Oritavancin Intravenous
- Empagliflozin and metformin-Orkambi
- Empagliflozin and metformin-Orkambi (Lumacaftor and Ivacaftor Granules)
- Empagliflozin and metformin-Orkambi (Lumacaftor and Ivacaftor Tablets)
- Orilissa-Empagliflozin and Metformin Extended-Release Tablets
- Orilissa-Empagliflozin and Metformin Tablets
- Orilissa-Empliciti
- Orilissa-Emsam
- Orilissa-Emsam Transdermal
- Orilissa-Emtricitabine